Bioprocessing of Adeno-Associated Viral vectors & Analytics

Adenovirus associated virus (AAV) vectors are increasingly used for gene therapy. Manufacturing of safe and efficacious clinical-grade virus relies on scalable and cost-effective production processes as well as good analytical technologies. We have developed an efficient process for AAV production in suspension cell culture to purified bulk product. The process was developed by evaluation and optimization of each process step. Cell culture conditions and triple plasmid transfection were optimized for transfection efficiency and AAV2 production. Purification was developed using filtration and chromatography technologies. Affinity and ion exchange-based purification step alternatives were compared. Finally, a robust and efficient analytical SPR-based assay was developed for AAV quantitation.

Speaker:
Mats Lundgren, PhD
Customer Applications Director, Cytiva

Mats has more than 25 years of experience in the field of biotechnology. He holds a PhD in Immunology, Cell and Molecular Biology from the Karolinska Institute, Stockholm, Sweden and extensive post-doc training at the MRC Clinical Sciences Centre, Imperial College School of Medicine in London, UK.

In his industrial career Mats has had positions as scientist, team manager and VP at Pharmacia, AstraZeneca and smaller biotech companies. In his previous function, Mats was managing both the Cell line and Upstream Process Development teams at a major biotech company. In his current role, Mats works across different viral vector and vaccine application projects as well as general upstream topics, focusing on customer support, applicability of new technologies and manufacturing solutions.